Make Informed Investment Decisions with Affordable Access to Experts
Edison Is Sponsoring a Call To Discuss the Evolving AML LandscapeTicker(s): JAZZ, ATNM, NVS, ABBV, SGEN, CELG, AGIO
Name: Dr Douglas Smith - MD
Institution: Johns Hopkins University
- Involved in the care of several hundred patients with AML at various stages of treatment (active and follow-up) and include newly diagnosed pts, relapsed, refractory, pre and post BMT
- Manages the leukemia clinical trials portfolio for AML for John Hopkin's large academic practice
- Confirmed very strong knowledge of clinical data for AML treatments
This expert call is sponsored by Edison, a global advisory and independent research company. Edison's world renowned equity research platform provides deep multi-sector knowledge and an extensive network of investors, advisors and companies providing clients with a differentiated approach to advisory services. This enables Edison to truly understand its clients’ businesses and their needs and to engage more fully with stakeholders on their behalf and in a more targeted way.
CALL LEADER: Maxim Jacobs, Director of Healthcare Research, North America
Maxim joined Edison in 2015 from Guidepoint Global, where he was a Director of Survey and Tracker Research, conducting extensive primary research across healthcare markets. He also brings more than 15 years’ experience in equities to the healthcare team previously holding positions at Ridgemark Capital, Broadfin Capital, and Mehta Partners.
Please describe your clinical practice and development experience as it relates to AML.Added By: joe_mccann
What pipeline products do you think are most likely to change the treatment paradigm for AML?Added By: joe_mccann
What impact will Vyxeos have on how you treat patients?Added By: joe_mccann
What specific subgroups within AML are those that have the greatest unmet medical need?Added By: joe_mccann
How do you see MRD evolving in AML and what role do you anticipate it will play in the next 3-5 years?
What do you estimate is the % of patient with AML who receive 7+3 (or other aggressive regimen) vs. HMA or low dose cytarabine?Added By: userda0312f6
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.